After learning of the warning letter, an investor accused Applied of knowing about these trial issues but not disclosing them ...
Clinical research firm Javara has laid off staff as part of a restructuring, a spokesperson confirmed to Fierce Biotech in an ...
As Cytokinetics’ aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights ...
California-based Apollomics had been testing uproleselan as an adjunct to chemotherapy in relapsed and refractory acute ...
A phase 3 trial of Novo Nordisk’s next-generation obesity prospect CagriSema has failed to achieve the level of weight loss ...
Nerve stimulation company electroCore has signed an agreement to acquire NeuroMetrix and its Quell wearable device aimed at ...
To develop RNA medicines targeting a proprietary bundle of tumor antigens, Epitopea is tapping nucleic acid delivery ...
The Swiss biopharma, which also manufactures insomnia med Quviviq, has been walking a financial tightrope for the last couple ...
Pyxis Oncology is shelving a clinical-stage monoclonal antibody to focus on its lead antibody-drug conjugate (ADC) after ...
Aadi pulls commercial-to-preclinical pivot, buying ADCs and selling approved drug to reboot business
Aadi Bioscience has rebooted its operations, transforming from a commercial business into a preclinical biotech by offloading ...
However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...
The FDA has denied Zealand Pharma’s approval bid for glepaglutide—a possible challenger to Takeda’s Gattex—in short bowel syndrome (SBS), citing a lack of evidence. | The FDA has denied Zealand Pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback